Clinical trial · people

Melanotan I: well tolerated in 6 acute stroke patients

Checked against the paper Clinical trialPublished by PepVault

The takeaway

This is a first small safety check of Melanotan I (afamelanotide) in stroke patients, not evidence that it improves stroke recovery.

Kind
Clinical trial
Studied in
People
Number studied
6
Published
2023
Journal
BMC Neurol

What they tested

The team tested whether afamelanotide (Melanotan I) could be given safely and practically to people within a day of an ischemic stroke, a stroke caused by a blocked blood vessel.

How the study was done

An open-label phase 2a trial in 6 people with acute ischemic stroke, with no comparison group and everyone knowing they got the drug. Patients were within 24 h of onset and could not get treatments to reopen the blocked vessel. They received 16 mg implants under the skin on days 0 and 1, repeated on days 7 and 8 for those not well recovered, and were followed with checks and brain scans up to day 42.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Melanotan I? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Of the 6 patients, 5 were women and the median age was 81. Two received 4 doses and four received 2. One patient died of a second stroke on day 9, tied to a known complete blockage of the internal carotid artery and judged unrelated to the drug, and no other local or major whole-body side effects were seen. In the survivors, the median NIHSS score, a stroke severity scale, went from 6 to 2 by day 7. The median area of poor blood flow on the first-day scan was 23 mL, and the area seen on later MRI scans measured 10 mL on day 3 and 4 mL on day 9.

What it doesn’t show

With only 6 patients and no control group, the trial cannot show whether the improvement came from the drug or from natural recovery after stroke. The authors say randomized studies are needed to test the benefit.

The paper

Stanislaus et al. A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial. BMC Neurol. 2023.

The compound

More studies on Melanotan I

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Melanotan I? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo